奥卡西平片致皮疹合并重度血小板减少1例

中国药物警戒 ›› 2018, Vol. 15 ›› Issue (6): 368-369.

奥卡西平片致皮疹合并重度血小板减少1例

郭濠宁, 吴思霖, 张莉, 何淼泉^*

四川省精神卫生中心·绵阳市第三人民医院,四川绵阳 621000）

收稿日期:2018-08-03 修回日期:2018-08-03 出版日期:2018-06-15 发布日期:2018-08-03
通讯作者: 何淼泉,男,本科,副主任药师 ,医院药学。
作者简介:郭濠宁,男,硕士,药师 ,临床药学。

One Case of Skin Rash and Severe Thrombocytopenia Induced by Oxcarbazepine Tablets

GUO Hao-ning, WU Si-lin, ZHANG Li, HE Miao-quan^*

Sichuan Mental Health Center·The Third Hospital of Mianyang, Sichuan Mianyang 621000, China

Received:2018-08-03 Revised:2018-08-03 Online:2018-06-15 Published:2018-08-03

摘要/Abstract

中图分类号:

R994.11

郭濠宁, 吴思霖, 张莉, 何淼泉. 奥卡西平片致皮疹合并重度血小板减少1例[J]. 中国药物警戒, 2018, 15(6): 368-369.

GUO Hao-ning, WU Si-lin, ZHANG Li, HE Miao-quan. One Case of Skin Rash and Severe Thrombocytopenia Induced by Oxcarbazepine Tablets[J]. Chinese Journal of Pharmacovigilance, 2018, 15(6): 368-369.

[1] Shankar B R.Quetiapine-induced leucopenia and thrombocytopenia[J]. Psychosomatics, 2007, 8(6): 530-531.
[2] 孙燕, 仵钊锋. 度洛西汀临床不良反应分析[J]. 河南大学学报(医学版), 2015,(2): 142-144.
[3] 王健, 马辛. 丙戊酸镁缓释片致血小板减少症1例[J]. 临床精神医学杂志, 2016, 26(3): 216.
[4] 汪作为, 陈银娣. 喹硫平所致血小板减少症1例[J]. 精神医学杂志, 2009, 22(5): 384.
[5] 李焕芬, 陈建华, 朱利芳. 奥卡西平片致血小板减少1例[J]. 中国药物警戒, 2015, 12(11): 700.
[6] 王丹. 诺华公司警告奥卡西平的严重皮肤反应[J]. 中国药物警戒, 2005, 2(4): 252.
[7] 杨华, 魏晶, 王嘉仡, 等. 药品不良反应/事件报告评价方法研究[J]. 中国药物警戒, 2009, 6(10): 581-584.
[8] 卫生部合理用药专家委员会. 中国医师药师临床用药指南[M]. 1版. 重庆: 重庆出版社, 2009: 1132-1133.
[9] Schmidt D, Elger C E.What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs?[J]. Epilepsy Behavior, 2004, 5(5): 627-635.
[10] 仇锦春, 廖清船, 张永, 等. 奥卡西平致皮疹、血小板减少性紫癜1例[J]. 中国现代应用药学, 2011, 28(11): 1067-1068.
[11] He X, Kang S, Wang F, et al.Oxcarbazepine-related thrombocytopenic purpura[J]. Journal of Clinical Psychopharmacology, 2011, 31(1): 137-138.
[12] 方舒, 龚志成. 奥卡西平的不良反应[J]. 中国当代儿科杂志, 2015, 17(4): 414-419.
[13] 何学莲, 王芳琳, 吴革菲, 等. 奥卡西平诱发的Stevens-Johnson综合征的临床特点及基因表达[J]. 中华实用儿科临床杂志, 2011, 26(5): 360-362.
[14] Tutorcrespo M J, Hermida J, Tutor J C.Relation of blood platelet count during carbamazepine and oxcarbazepine treatment with daily dose, and serum concentrations of carbamazepine, carbama-zepine-10,11-epoxide, and 10-hydroxycarbazepine[J]. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2007, 151(1): 91-94.
[15] Hurley J S, Roberts M, Solberg L I.Laboratory safety monitoring of chronic medications in ambulatory care settings[J]. J Gen Intern Med, 2005, 20(4): 331-333.
[16] Martinez W, Ingenito A, Blakeslee M, et al.Efficacy, safety, and tolerability of oxcarbazepine monotherapy[J]. Epilepsy Behavior, 2006, 9(3): 448-456.